Potential Of IL-33 As A Novel Myokine In Sarcopenia-Osteoporosis Communication: Insights From Mendelian Randomization
As we age, many people experience a chronic, low-grade inflammation, a process scientists call “inflammaging.” This persistent inflammation is increasingly linked to various age-related conditions, including the weakening of muscles (sarcopenia) and the thinning of bones (osteoporosis). Our muscles and bones are not isolated; they constantly communicate through various signaling molecules, some of which are released by muscle cells and are known as “myokines.”
Researchers recently investigated the role of several inflammatory proteins in this muscle-bone conversation, specifically looking for causal links using a powerful genetic approach called Mendelian Randomization. This method helps determine if a factor truly causes an outcome, rather than just being associated with it.
The findings highlighted a particular protein, Interleukin-33 (IL-33), as a key player. The study revealed a causal connection: individuals with weaker handgrip strength, a common indicator of sarcopenia, tended to have lower levels of IL-33. Furthermore, these lower levels of IL-33 were causally associated with an increased risk of developing osteoporosis. This suggests that IL-33, acting as a myokine, is crucial for maintaining healthy communication between muscles and bones.
This discovery is significant because it points to IL-33 as a promising new target for therapies aimed at improving both muscle and bone health in older adults. By understanding and potentially manipulating this muscle-bone communication pathway, we might be able to develop new strategies to combat sarcopenia and osteoporosis simultaneously. While these insights are exciting, further experimental studies are needed to fully understand the mechanisms and validate IL-33’s therapeutic potential.
Source: link to paper